Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDUFA Commitment Letter Formalizes REMS Standardization Schedule

This article was originally published in The Pink Sheet Daily

Executive Summary

Among other timetables set as part of the broad deal with industry, FDA will host meetings and issue guidances to assess and minimize the burden of REMS on the practitioners and patients.
Advertisement

Related Content

Rare Disease Integration Into FDA Reviews Will Grow Under PDUFA VI
iPLEDGE Again On FDA Advisory Agenda, This Time As An Example
PDUFA V Commitment Letter Front-Loads Guidance, Meeting Milestones
FDA Must Codify Flexibility For Rare Diseases, Coté Says As He Moves To NORD
How "Clean" Will PDFUA V Be? Rep. Pitts Explains His Vacuuming Technique
Orphan Drugs Need Easier, Speedier Approval, Not More Exclusivity, CEO Says
PDUFA V Agreement Set In Four Areas, But Broad FDA/Industry Talks Continue
PDUFA V: FDA Application Completeness Crackdown Continues
REMS Templates Get Nod From FDA, With Nudge From Pharmacists
REMS Templates Get Nod From FDA, With Nudge From Pharmacists

Topics

Advertisement
UsernamePublicRestriction

Register

PS072752

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel